The groundbreaking success of Sildenafil undeniably revolutionized the pharmaceutical landscape, but placing funds in companies strongly reliant on unbranded versions presents a complex picture. While early returns were significant, the cessation of patents and the emergence of discounted alternatives have eroded sales. Consequently, a thorough ass